Journal Scans
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Efficacy of PEG-IFN-Alfa-2a in Essential Thrombocythemia and Polycythemia Vera
A Quintás-Cardama , H Kantarjian, T Manshouri, R Luthra, Z Estrov, S Pierce, MA Richie, G Borthakur, M Konopleva, J Cortes, S Verstovsek
20090913
2009 Oct 13
J Clin Oncol
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
J Clin Oncol. 2009 Oct 13; Epub ahead of print, A Quintás-Cardama , H Kantarjian, T Manshouri, R Luthra, Z Estrov, S Pierce, MA Richie, G Borthakur, M Konopleva, J Cortes, S Verstovsek
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative disorders that can evolve to myelofibrosis or progress to acute myeloid leukemia. The JAK2V617F mutation may serve as a useful molecular marker of response to treatment in these myeloproliferative disorders, being detected in 95% of PV cases and in 50% to 60% of ET cases. Management of low-risk ET and PV includes aspirin for prevention of thrombotic events. For high-risk disease, hydroxyurea remains the sole agent available...
